Penumbra Stock News

Penumbra (PEN) delivered earnings and revenue surprises of -47.37% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (NYSE:PEN) is scheduled to announce Q4 earnings results on Tuesday, February 22nd, after market close.The consensus EPS Estimate is $0.22 (-47.6% Y/Y) and the consensus

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALAMEDA, Calif., Feb. 10, 2022 /PRNewswire/ -- Penumbra, Inc. today announced that its management team is scheduled to present at Citi''s 2022 Virtual Healthcare Conference on Thursday,… | February 10, 2022

ALAMEDA, Calif., Feb. 10, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at Citi''s 2022 Virtual Healthcare Conference on Thursday, February 24, 2022. Event: Citi''s 2022 Virtual Healthcare Conference Date: Thursday, February

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.

Penumbra Inc (PEN) shares closed 4.6% lower than its previous 52 week low, giving the company a market cap of $7B. The stock is currently down 27.2% year-to-date, down 21.2% over the past 12 months, and up 184.4% over the past five years. This week, the Dow Jones Industrial Average fell 2.5%, and the S&P 500 fell 4.1%. Trading Activity Trading volume this week was 35.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 708.4% The company's stock price performance over the past 12 months lags the peer average by 297.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -993.8% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Penumbra Inc (NYSE: PEN) is exploring a potential deal with Shockwave Medical Inc (NASDAQ: SWAV), Bloomberg reported citing people with knowledge of the matter. According to the people, Penumbra

Shares of Penumbra, Inc. (NYSE:PEN) have earned an average rating of Buy from the eight research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12 month price target among brokers that []

Related Stocks: ARGX , MGNX , CUTR , RNA , FULC , ITOS , TMO , PEN , TNYA , SGHT , AADI , RCOR , PTGX , MDXG , CSTL , AGEN , ABUS , QDEL , TRIL , CHAQ , BCTG , ITMR , RACA ,

ALAMEDA, Calif., Dec. 22, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 40 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022.

ALAMEDA, Calif., Dec. 22, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 40th Annual J.P.

State of New Jersey Common Pension Fund D cut its position in shares of Penumbra, Inc. (NYSE:PEN) by 1.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 20,684 shares of the companys stock after selling 236 shares during the period. State []

Zacks Investment Research lowered shares of Penumbra (NYSE:PEN) from a hold rating to a sell rating in a research report released on Tuesday, Zacks.com reports. According to Zacks, Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The companys portfolio of products primarily addresses neuro and peripheral vascular medical []